DHJJ Financial Advisors Ltd. Takes $56,000 Position in AstraZeneca PLC $AZN

DHJJ Financial Advisors Ltd. acquired a new stake in AstraZeneca PLC (NASDAQ:AZN) in the second quarter, HoldingsChannel.com reports. The fund acquired 800 shares of the company’s stock, valued at approximately $56,000.

Other hedge funds also recently made changes to their positions in the company. Dynamic Advisor Solutions LLC lifted its position in shares of AstraZeneca by 58.4% in the first quarter. Dynamic Advisor Solutions LLC now owns 13,055 shares of the company’s stock valued at $960,000 after buying an additional 4,811 shares during the last quarter. SCS Capital Management LLC acquired a new stake in shares of AstraZeneca in the first quarter valued at approximately $3,066,000. Robbins Farley acquired a new stake in AstraZeneca during the 2nd quarter worth approximately $1,857,000. Farther Finance Advisors LLC lifted its holdings in AstraZeneca by 13.1% during the 1st quarter. Farther Finance Advisors LLC now owns 6,083 shares of the company’s stock worth $442,000 after purchasing an additional 706 shares during the last quarter. Finally, Oliver Luxxe Assets LLC lifted its holdings in AstraZeneca by 6.0% during the 2nd quarter. Oliver Luxxe Assets LLC now owns 78,301 shares of the company’s stock worth $5,472,000 after purchasing an additional 4,449 shares during the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Price Performance

AstraZeneca stock opened at $85.31 on Friday. The stock’s fifty day moving average price is $78.04 and its two-hundred day moving average price is $73.10. AstraZeneca PLC has a one year low of $61.24 and a one year high of $85.50. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. The firm has a market cap of $264.58 billion, a PE ratio of 32.07, a price-to-earnings-growth ratio of 1.54 and a beta of 0.36.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 EPS for the quarter, hitting analysts’ consensus estimates of $1.09. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The firm had revenue of $14.46 billion for the quarter, compared to analyst estimates of $14.08 billion. During the same quarter last year, the company earned $1.24 EPS. The company’s revenue was up 16.1% on a year-over-year basis. As a group, research analysts expect that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Monday, September 8th. Shareholders of record on Friday, August 8th were paid a dividend of $0.505 per share. This represents a yield of 200.0%. The ex-dividend date was Friday, August 8th. AstraZeneca’s dividend payout ratio (DPR) is 37.97%.

Analyst Ratings Changes

Several analysts recently weighed in on AZN shares. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a report on Saturday, September 27th. Berenberg Bank set a $97.00 price target on AstraZeneca in a report on Wednesday, July 9th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $86.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.